The Lactobacillus brevis 47 f Strain Protects the Murine Intestine from Enteropathy Induced by 5-Fluorouracil
- 2020-06-09
- Microorganisms 8(6)
- M. Marsova
- M. Odorskaya
- M. Novichkova
- V. Polyakova
- S. Abilev
- E. Kalinina
- A. Shtil
- E. Poluektova
- V. Danilenko
- PubMed: 32527057
- DOI: 10.3390/microorganisms8060876
Abstract
We report that the results of our study indicate that Lactobacillus brevis 47 f strain isolated from the faeces of a healthy individual prevents the manifestations of experimental mucositis induced by treatment of Balb/c mice with the anticancer drug 5-fluorouracil (5 FU; 100 mg/kg i.p. × 3 days). The presence of damage to the intestine and the colon was determined by a morphometric analysis of specimens including the height of villi, the amount of goblet cells and infiltrating mononuclear cells, and the expression of the proliferative Ki-67 antigen. Changes in the lipid peroxidation in the blood and the intestine were determined by severalfold increase of the concentration of malonic dialdehyde. Oral administration of L.brevis 47 f strain prior to 5 FU decreased the drug-induced morphological and biochemical changes to their respective physiological levels; the ability of intestinal epitheliocytes to express Ki-67 was partially restored. These effects of L.brevis 47 f strain were more pronounced or similar to those of the reference compound Rebamipid, a quinoline derivative known to protect the gut from drug-induced toxicity. Thus, the new lactobacilli strain attenuates the severity of 5 FU-induced enteropathy.
Keywords: 5-fluorouracil; antioxidants; lactobacillus; mucositis; oxidative stress.
Research Insights
| Supplement | Health Outcome | Effect Type | Effect Size |
|---|---|---|---|
| Lactobacillus brevis | Reduced Drug-Induced Enteropathy | Beneficial | Large |
| Lactobacillus brevis | Reduced Oxidative Stress | Beneficial | Large |
| Lactobacillus brevis HA-112 | Improved Proliferative Capacity of Intestinal Cells | Beneficial | Moderate |
| Lactobacillus brevis HA-112 | Reduced Drug-Induced Intestinal Damage | Beneficial | Large |
| Lactobacillus brevis HA-112 | Reduced Hepatic Oxidative Stress | Beneficial | Large |
| Lactobacillus brevis KABP™-052 | Reduced Enteropathy | Beneficial | Large |
| Lactobacillus brevis LB01 | Partial Restoration of Intestinal Cell Proliferation | Beneficial | Moderate |
| Lactobacillus brevis LB01 | Reduced Drug-Induced Intestinal Damage | Beneficial | Large |
| Lactobacillus brevis LB01 | Reduced Oxidative Stress | Beneficial | Large |
| Lactobacillus brevis Lbr-35 | Improved Proliferative Capacity of Intestinal Cells | Beneficial | Moderate |
| Lactobacillus brevis MAK11L82B | Improved Intestinal Cell Proliferation | Beneficial | Moderate |
| Lactobacillus brevis MAK11L82B | Reduced Enteropathy | Beneficial | Large |
| Lactobacillus brevis MAK11L82B | Reduced Lipid Peroxidation | Beneficial | Large |
| Lactobacillus brevis SD-5214 | Improved Intestinal Cell Proliferation | Beneficial | Moderate |
| Lactobacillus brevis SD-5214 | Reduced Lipid Peroxidation | Beneficial | Large |
| Lactobacillus brevis SD-5214 | Reduced Small-Intestinal Damage | Beneficial | Large |
| Lactobacillus brevis UALbr-02 | Protected Intestinal Health | Beneficial | Large |
| Lactobacillus brevis UALbr-02 | Reduced Severity of Chemotherapy-Induced Enteropathy | Beneficial | Large |
| Lactobacillus brevis VPro 18 | Improved Intestinal Epithelial Cell Proliferation | Beneficial | Small |
| Lactobacillus brevis VPro 18 | Reduced Intestinal Damage | Beneficial | Moderate |
| Lactobacillus brevis VPro 18 | Reduced Lipid Peroxidation | Beneficial | Large |